Data Transparency Platform for Clinical Trials
TrialScope is a clinical trial management platform that ensures compliance processes are consistently implemented while optimising disclosure activities and trial data transparency.
This flexible and customisable platform is designed to inform and engage patients through open research sharing. It supports clinical trial disclosure and transparency, from registration to final report summaries.
TrialScope improves patient recruitment and engagement, as well as promotes simplified and validated data-sharing across all of its corporate websites. The platform is intuitive, easy-to-use, and connects data in real-time, which ensures that trial information is promptly displayed for both internal and public viewing.
TrialScope is currently used in 40% of industry trials registered on ClinicalTrials.gov and EudraCT. Today, more than 12,000 users manage more than 30,000 clinical trials using TrialScope’s technologies.
TrialScope DiscloseTM centralises, tracks and registers clinical trial data in compliance with disclosure processes. The system mitigates compliance risks and provides greater control over disclosure reputation.
The platform’s comprehensive, Cloud-based software includes a full range of capabilities for compliant, confident clinical trial disclosure, from protocol to registration to results.
TrialScope EngageTM enables clinical trial sponsors to engage with patients and the public via a user-friendly, high-impact website.
The site openly shares clinical trial information and results, demonstrating leadership in transparency. It also optimises recruitment and patient retention.
TrialScope Engage enables sponsors to deliver clear communications via the clinical trial publication website, and ensuring only pre-approved and accurate trial information is shared using real-time connectivity to ClinicalTrials.gov and TrialScope Disclose platforms.
TrialScope is one of the most widely used global clinical trial disclosure and transparency management platforms in the world. It offers disclosure services that can be used in conjunction with the platform’s state-of-the-art software to make disclosure efforts more accurate and efficient.
The services are scalable, so clients can adjust the parameters to accommodate their changing workload.
Utilising an established, data-driven evaluation methodology, TrialScope’s advisory services provide clinical trial sponsors with vital disclosure and transparency reviews and recommendations. These prepare sponsors for pending inspections and help improve assessment results.
TrialScope’s experts offer concrete metrics and best practice recommendations to achieve compliant, efficient clinical trial disclosure that also meets evolving transparency trends.
TrialScope DiscloseTM delivers the proven solutions clinical trial sponsors need to centralise, track, register and comply with clinical trial disclosure processes, mitigating compliance risks while giving them greater control over their own clinical trial disclosure reputation.
TrialScope EngageTM enables clinical trial sponsors to engage with patients and the public via a user-friendly, high-impact website to openly share clinical trial information and results, demonstrating leadership in transparency while optimizing trial recruitment and retention.
TrialScope is more than just one of the most widely used global clinical trial disclosure and transparency management platforms. It also offers disclosure services that, when used in conjunction with its state-of-the-art software, makes your disclosure efforts more accurate and efficient than ever before. TrialScope’s services are scalable, so you can adjust to accommodate your changing workload.
Utilising an established, data-driven evaluation methodology, TrialScope's advisory services provides clinical trial sponsors with vital disclosure and transparency reviews and recommendations that not only prepare sponsors for pending inspections but also help them improve ranking in assessments by transparency advocates.
This short video explains why 13 of the top 15 pharmaceutical sponsors partner with TrialScope to manage disclosure and registration of more than 30,000 global clinical trials.
Trial results summaries, also known as plain language summaries (PLS) or lay language summaries, convey what happened during a clinical trial in easy-to-understand language.
With increased scrutiny from regulatory agencies, advocacy groups and the public for clinical trial transparency, sponsors are feeling the pressure to ramp up efforts to make their studies more accessible.
Emulate inaugurated a new headquarters and laboratory at Drydock Avenue in Seaport District, Boston, in February 2016.
TrialScope has collaborated with EMD Serono to launch an innovative clinical trials website: https://clinicaltrials.emdgroup.com.
Leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device and diagnostics industries PM360 selected TrialScope’s clinical trial transparency service known as TrialScope Engage as one of the most innovative services of 2018 in the life sciences industry.
TrialScope’s strategic partnership with nonprofit organization Vivli offers sponsors and researchers access to the most complete solution for disclosure and data sharing.
TrialScope has been named a finalist for Best Patient-Focused Technological Development in the CARE Awards, which recognise outstanding work across the global clinical research enterprise.
TrialScope has been recognised by CIOReview as one of 2016's 20 Most Promising Pharma and Life Sciences Tech Solution Providers.
TrialScope has recently conducted its Clinical Trial Transparency Leadership Forum, as part of its Transparency Leadership series.
TrialScope will be in Philadelphia for the CBI Prep Forum for the New EU Clinical Trial Regulation.
TrialScope has announced it has relocated its headquarters to a larger space that accommodates the rapid growth the company has experienced and the expected growth in the next few years.
TrialScope has announced the release of Convert, a free online clinical trial data conversion service.
TrialScope has announced two executive appointments. Brian Flaherty will be vice-president of Business Development and Thomas Wicks has been appointed chief strategy officer (CSO).
Bridge Capital Holdings, whose subsidiary is Bridge Bank, announced it has provided TrialScope with a $2 million revolving credit facility based on monthly recurring revenue.
TrialScope has announced general availability of the latest release of the PharmaCM platform v.2.2.
TrialScope announced it has appointed Richard Aguinaldo as chief financial officer (CFO).
Harborside Five
185 Hudson Street, Suite 2900
Jersey City, NJ 07311
07311
New Jersey
United States of America
Harborside Financial Center
Plaza Five, Suite 2900
Jersey City
07311
New Jersey
United States of America